Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Eisai will acquire MOGN for $41 per share, or about $3.9 billion, in cash. The price is a 23% premium to MOGN's close
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury